Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.

@article{Bahl2004TolerabilityOT,
  title={Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status.},
  author={Mala Bahl and Lillian L. Siu and Gregory R. Pond and John Kim and Ian F. Tannock and Andrew John Bayley and Bernard J. Cummings and John Waldron and Jolie Ringash and Eric Chen and Leah Gitterman and Betty Lemon and Brian O'Sullivan},
  journal={International journal of radiation oncology, biology, physics},
  year={2004},
  volume={60 4},
  pages={1127-36}
}
PURPOSE The Intergroup 0099 trial (INT 0099) for locally advanced nasopharyngeal cancer (NPC) has set a standard of practice. This retrospective review documents our institutional experience with this regimen. METHODS AND MATERIALS For all NPC patients treated between January 1998 and December 2002 with the INT 0099 regimen, compliance, toxicity, weight change, and feeding tube use were recorded. Patients were grouped by therapy completion status and by feeding tube status. RESULTS Of 78… CONTINUE READING